Aimmune Therapeutics, Inc. (NASDAQ:AIMT) CEO Stephen George Dilly sold 80,110 shares of Aimmune Therapeutics stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $26.23, for a total value of $2,101,285.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Stephen George Dilly also recently made the following trade(s):

  • On Friday, October 6th, Stephen George Dilly sold 4,047 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.31, for a total value of $106,476.57.
  • On Thursday, October 5th, Stephen George Dilly sold 14,689 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.24, for a total value of $385,439.36.
  • On Monday, September 25th, Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $25.01, for a total value of $2,501,000.00.
  • On Wednesday, July 26th, Stephen George Dilly sold 50,000 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $21.46, for a total value of $1,073,000.00.

Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) traded down 3.21% during midday trading on Friday, reaching $25.36. The company’s stock had a trading volume of 405,650 shares. The stock’s market capitalization is $1.28 billion. Aimmune Therapeutics, Inc. has a 52 week low of $14.87 and a 52 week high of $27.31. The company has a 50 day moving average price of $24.28 and a 200-day moving average price of $24.28.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). On average, equities research analysts expect that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/06/stephen-george-dilly-sells-80110-shares-of-aimmune-therapeutics-inc-aimt-stock.html.

Several brokerages have weighed in on AIMT. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Wedbush reissued an “ourperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, August 14th. BidaskClub cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $38.00 price objective on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, July 27th. Finally, ValuEngine raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. Aimmune Therapeutics currently has an average rating of “Hold” and an average target price of $40.00.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its holdings in shares of Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after buying an additional 499 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Aimmune Therapeutics by 454.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock worth $130,000 after buying an additional 4,900 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC increased its holdings in shares of Aimmune Therapeutics by 31.2% during the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after buying an additional 3,757 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Aimmune Therapeutics during the 2nd quarter worth approximately $333,000. 72.90% of the stock is currently owned by institutional investors and hedge funds.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.